Japanese startups, funding rounds and venture investment.
Japan counted 6,220 university spinouts in October 2025, more than double the 2,905 five years earlier. A gene-edited sea bream and a pigment-free coating are the way in. Each Japanese listing raises only $28 million.
Japan has begun selling Telomelysin, a rewired cold virus that multiplies only inside cancer cells and goes into esophageal tumors by endoscope. Three doses list at 9.3 million yen; the trial behind it had 37 patients.
ZEALS opened orders for D1, a 129.3 cm Japanese humanoid, from 5 million yen (about $32,000). Why the company calls it semi-domestic rather than fully Japanese, and why 100 units and 10,000 hours is a modest goal.
AIST and Tokyo startup OptQC have switched on MoQuren, a photonic quantum computer that needs no refrigerator and no vacuum chamber. What it can do now, and how Japan's bet differs from the US and China.
Keio University reports up to four years of follow-up on four patients given iPS-derived cells for spinal cord injury: no tumors, no serious harm. What it means, and how Japan's path compares to the US and Europe.
An Osaka University startup, Endoluminal Solutions, has built a 4mm single-use endoscope aimed at replacing barium gastric-cancer screening. A look at the miniaturization behind it and where it fits in an endoscope industry Japan's Olympus dominates.
Telomelysin, a common-cold virus reprogrammed to destroy cancer cells, has won the world's first approval for esophageal cancer. It took 35 years, one surgeon's idea, and an Okayama University startup pushing through a regulatory maze.
Tohoku University spinoff Space Quarters has demonstrated its DAIQ orbital assembly robot system on a ground model, showing three kinds of small robots cooperating to pick, place, and weld building panels into a larger structure. We look at how it compares to NASA's cancelled OSAM-1 and DARPA's NOM4D, and what makes Japan's robotics approach distinct.
Yokohama National University spinoff LQUOM has closed a 1.23 billion yen ($7.7M) Series B to build quantum repeaters, the missing piece of the quantum internet. Here is what that means, and how it stacks up against Aliro in the US, USTC in China, and Japan's planned Tokyo-Osaka quantum backbone.
Kyoto University spinout Toregem Biopharma will begin Phase 2 trials of TRG035, the world's first tooth-regeneration drug, in summer 2026, dosing 24 children with congenital tooth agenesis. A pre-Series C round of ¥850 million brings cumulative funding, grants included, past ¥4.6 billion. A look at how Japan's university-biotech funding stack works, and why a super-aged society may produce this kind of innovation first.
In 2012, the Sankei Shimbun reported a biofuel revolution centered on Enomoto algae, a hyper-growth Botryococcus bred by Kobe University spin-off G> under Professor Taira Enomoto. Heavy-industry giant IHI joined biotech venture Neo-Morgan Laboratory to commercialize it, with then-CEO Tomohiro Fujita declaring he wanted to cut the price to one-tenth within ten years. Fourteen years later, the joint venture has dissolved, but the algae fueled the world's first flight on SAF meeting ASTM D7566 Annex 7, and a Japanese-led 5-hectare facility in Malaysia is now the largest of its kind on Earth. Did the promise come true, or is the dream over?